- Home
- CRVS vs ZIMV Comparison
CRVS vs ZIMV Comparison
Compare CRVS & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- ZIMV
- Stock Information
- Founded
- CRVS 2014
- ZIMV 2021
- Country
- CRVS United States
- ZIMV United States
- Employees
- CRVS N/A
- ZIMV N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CRVS Health Care
- ZIMV Health Care
- Exchange
- CRVS Nasdaq
- ZIMV Nasdaq
- Market Cap
- CRVS 459.0M
- ZIMV 532.3M
- IPO Year
- CRVS 2016
- ZIMV N/A
- Fundamental
- Price
- CRVS $5.79
- ZIMV $18.88
- Analyst Decision
- CRVS Strong Buy
- ZIMV Hold
- Analyst Count
- CRVS 4
- ZIMV 3
- Target Price
- CRVS $15.00
- ZIMV $14.50
- AVG Volume (30 Days)
- CRVS 547.2K
- ZIMV 645.0K
- Earning Date
- CRVS 11-11-2025
- ZIMV 10-29-2025
- Dividend Yield
- CRVS N/A
- ZIMV N/A
- EPS Growth
- CRVS N/A
- ZIMV N/A
- EPS
- CRVS N/A
- ZIMV N/A
- Revenue
- CRVS N/A
- ZIMV $443,402,000.00
- Revenue This Year
- CRVS N/A
- ZIMV $2.49
- Revenue Next Year
- CRVS N/A
- ZIMV $1.26
- P/E Ratio
- CRVS N/A
- ZIMV N/A
- Revenue Growth
- CRVS N/A
- ZIMV N/A
- 52 Week Low
- CRVS $2.54
- ZIMV $8.15
- 52 Week High
- CRVS $10.00
- ZIMV $19.01
- Technical
- Relative Strength Index (RSI)
- CRVS 56.88
- ZIMV 74.50
- Support Level
- CRVS $5.64
- ZIMV $18.85
- Resistance Level
- CRVS $6.09
- ZIMV $18.93
- Average True Range (ATR)
- CRVS 0.34
- ZIMV 0.05
- MACD
- CRVS -0.05
- ZIMV -0.16
- Stochastic Oscillator
- CRVS 50.00
- ZIMV 23.53
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.